Javier Amézaga1, Begoña Alfaro1, Yolanda Ríos1, Aitziber Larraioz2, Gurutze Ugartemendia2, Ander Urruticoechea2, Itziar Tueros3. 1. AZTI, Food and Health, Parque Tecnológico de Bizkaia, Astondo Bidea 609, 48160, Derio, Bizkaia, Spain. 2. Onkologikoa Foundation, Paseo Doctor Begiristain 121, 20014, San Sebastián, Gipuzkoa, Spain. 3. AZTI, Food and Health, Parque Tecnológico de Bizkaia, Astondo Bidea 609, 48160, Derio, Bizkaia, Spain. itueros@azti.es.
Abstract
PURPOSE: Taste and smell changes are common side effects in cancer patients undergoing chemotherapy treatments (CT). This can lead to a reduced food enjoyment and an inadequate nutrient intake with a high impact on nutritional status and quality of life. The aim of this study was to evaluate the self-reported chemosensory alterations of patients undergoing chemotherapy according to CT type. METHODS: An observational study was conducted with 151 patients undergoing CT at Oncology Outpatient Unit from Onkologikoa Foundation. An interviewer-assisted questionnaire was designed to investigate chemosensory changes in patients undergoing CT. RESULTS: Seventy-six percent patients reported taste disorders and 45% smell changes. Xerostomia is the most frequent symptom reported by patients receiving chemotherapy in our study (63.6%), and it is strongly associated to bad taste in mouth (OR = 5.96; CI = 2.37-14.94; p value = 0.000) and taste loss (OR = 5.96; CI = 2.37-14.94; p value = 0.000). Anthracyclines, paclitaxel, carboplatin, and docetaxel were the CT agents producing the highest taste disturbance rates. Cisplatin and 5-Fluorouracil are the CT resulting in the lowest complaints. Logistic regression revealed statistically significant associations between taste loss and carboplatin and docetaxel (OR = 3.50; CI = 1.12-10.90; p value = 0.031) and cold hypersensitivity and oxaliplatin (OR = 12.14; CI = 4.18-35.25; p value = 0.000). Not only platin-based CT such as carboplatin produced dysgeusia, but also anthracyclines and paclitaxel treatments. CONCLUSIONS: The better knowledge of taste and smell alterations according to CT type may provide valuable information for the design of new strategies to tackle CT side effects. It is important to take into account taste and smell dysfunctions and other alterations such as xerostomia together.
PURPOSE: Taste and smell changes are common side effects in cancerpatients undergoing chemotherapy treatments (CT). This can lead to a reduced food enjoyment and an inadequate nutrient intake with a high impact on nutritional status and quality of life. The aim of this study was to evaluate the self-reported chemosensory alterations of patients undergoing chemotherapy according to CT type. METHODS: An observational study was conducted with 151 patients undergoing CT at Oncology Outpatient Unit from Onkologikoa Foundation. An interviewer-assisted questionnaire was designed to investigate chemosensory changes in patients undergoing CT. RESULTS: Seventy-six percent patients reported taste disorders and 45% smell changes. Xerostomia is the most frequent symptom reported by patients receiving chemotherapy in our study (63.6%), and it is strongly associated to bad taste in mouth (OR = 5.96; CI = 2.37-14.94; p value = 0.000) and taste loss (OR = 5.96; CI = 2.37-14.94; p value = 0.000). Anthracyclines, paclitaxel, carboplatin, and docetaxel were the CT agents producing the highest taste disturbance rates. Cisplatin and 5-Fluorouracil are the CT resulting in the lowest complaints. Logistic regression revealed statistically significant associations between taste loss and carboplatin and docetaxel (OR = 3.50; CI = 1.12-10.90; p value = 0.031) and cold hypersensitivity and oxaliplatin (OR = 12.14; CI = 4.18-35.25; p value = 0.000). Not only platin-based CT such as carboplatin produced dysgeusia, but also anthracyclines and paclitaxel treatments. CONCLUSIONS: The better knowledge of taste and smell alterations according to CT type may provide valuable information for the design of new strategies to tackle CT side effects. It is important to take into account taste and smell dysfunctions and other alterations such as xerostomia together.
Authors: R S Wickham; M Rehwaldt; C Kefer; S Shott; K Abbas; E Glynn-Tucker; C Potter; C Blendowski Journal: Oncol Nurs Forum Date: 1999-05 Impact factor: 2.172
Authors: Laurel Lyckholm; Steven P Heddinger; Gwendolyn Parker; Patrick J Coyne; Viswanathan Ramakrishnan; Thomas J Smith; Robert I Henkin Journal: J Pain Palliat Care Pharmacother Date: 2012-06
Authors: Anne Kathrine Larsen; Christine Thomsen; Mathilde Sanden; Lotte Boa Skadhauge; Camilla Bundgaard Anker; Marie Nerup Mortensen; Wender L P Bredie Journal: Support Care Cancer Date: 2021-06-02 Impact factor: 3.603
Authors: Alissa Nolden; Paule V Joseph; Kord M Kober; Bruce A Cooper; Steven M Paul; Marilyn J Hammer; Laura B Dunn; Yvette P Conley; Jon D Levine; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2019-07-23 Impact factor: 3.612
Authors: Cássia Emanuella Nóbrega Malta; Joyce Ohana de Lima Martins; Anna Clara Aragão Matos Carlos; Milena Oliveira Freitas; Iana Aragão Magalhães; Hérica Cristina Alves de Vasconcelos; Isabelly Joyce de Lima Silva-Fernandes; Paulo Goberlânio de Barros Silva Journal: Support Care Cancer Date: 2021-07-20 Impact factor: 3.603